Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
Bartz R, Fukuchi K, Ohtsuka T, Lange T, Gruner K, Watanabe I, Hayashi S, Oda Y, Kawaida R, Komori H, Kashimoto Y, Wirtz P, Mayer JA, Redondo-Müller M, Saito S, Takahashi M, Hanzawa H, Imai E, Martinez A, Hanai M, Häussinger D, Chapman RW, Agatsuma T, Bange J, Abraham R.
Bartz R, et al. Among authors: ohtsuka t.
Mol Cancer Ther. 2019 Oct;18(10):1832-1843. doi: 10.1158/1535-7163.MCT-18-0048. Epub 2019 Jul 26.
Mol Cancer Ther. 2019.
PMID: 31350344